Goodbye To All That: EMA Leaves London After 24 years
March 1 saw the official departure of the European Medicines Agency for Amsterdam. The move from London, which is a result of the UK's decision to leave the EU, has caused huge upheaval for the agency, which has been in the UK capital since it was created in 1995.
You may also be interested in...
Practically all centralized marketing authorizations held in the UK have now been moved to the EU, but Brexit and the European Medicines Agency’s relocation to Amsterdam are still causing the EMA some staffing and resource headaches.
An opinion on whether bluebird bio’s transfusion-dependent β-thalassemia gene therapy, LentiGlobin, should be granted an EU marketing authorization is due this week as the EMA’s key scientific committee, the CHMP, meets for the first time in Amsterdam.
The drug maker looks set to join fellow Japanese firms Sony and Panasonic in moving its European legal base out of the UK as the uncertainties surrounding Brexit show little sign of being resolved.